A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Access the Safety, Pharmacokinetics, and Pharmacodynamics of ICA-17043 in Patients with Sickle Cell Disease who are in the Steady, Non-Crisis State

Grants and Contracts Details

StatusFinished
Effective start/end date12/11/002/28/02

Funding

  • ICAgen Inc: $46,911.00